FOCUS Trial: CA4P in Patients with Platinum Resistant Ovarian Cancer

Description: Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics in South San Francisco, CA. The FOCUS trial is a double-blind, randomized, phase 2/3 clinical study evaluating the efficacy and safety of physician’s choice chemotherapy plus bevacizumab and CA4P versus physician’s choice chemotherapy plus bevacizumab and placebo in patients with platinum-resistant ovarian cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL
Shared By : AnnualMeeting2017
Posted on : 06/02/17
Added : 6 months ago
Category : Ovarian Cancer


Nothing found.

More From AnnualMeeting2017

Nothing found.